RHYTHM PHARMACEUTICALS, INC.
RHYTHM PHARMACEUTICALS, INC. (RYTM): 11 pipeline candidates · 5 upcoming catalysts · ~24 mo cash runway · 16 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
24.0 months
D/E 1.67 · 0% dilution
Lead: Approved
11 candidates
5 upcoming, next in ~12d
0 buys · 25 sells (180d)
A transparent, data-derived signal for RHYTHM PHARMACEUTICALS, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$6.6B
Cash
$62.1M
Quarterly Burn
$44.2M
Runway
24.0 mo
Revenue
$60.1M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (11 candidates)
| Drug | Phase |
|---|---|
| amplia mri crt-d | — |
| Bivamelagon | Phase 2 |
| capsure | — |
| capsure sp | — |
| IMCIVREE | Approved |
| LB54640 | Phase 2 |
| marquis/maximo/intrinsic icds | — |
| meta dddr pacing system | Approved |
| RM-718 | Phase 1/Phase 2 |
| Setmelanotide | Phase 2 |
Showing 10 of 11 candidates. Sign up for full pipeline.
Upcoming Catalysts (5)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
286
Total value held
$6.86B
| Holder | Shares | Value |
|---|---|---|
| ra capital management, l.p. | 6,666,837 | $579.8M |
| blackrock, inc. | 6,237,151 | $542.4M |
| vanguard capital management llc | 5,935,650 | $516.2M |
| baker bros. advisors lp | 5,604,483 | $487.4M |
| perceptive advisors llc | 4,747,590 | $412.9M |
| primecap management co/ca/ | 3,417,509 | $297.2M |
| vanguard portfolio management llc | 3,040,718 | $264.5M |
| state street corp | 2,271,851 | $197.6M |
| goldman sachs group inc | 1,965,432 | $170.9M |
| westfield capital management co lp | 1,929,123 | $167.8M |
Showing top 10 of 286 institutional holders of RHYTHM PHARMACEUTICALS, INC.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in RHYTHM PHARMACEUTICALS, INC.'s pipeline?
RHYTHM PHARMACEUTICALS, INC. (RYTM) has 11 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is RHYTHM PHARMACEUTICALS, INC.'s next catalyst?
RHYTHM PHARMACEUTICALS, INC.'s next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: setmelanotide" — expected June 30, 2026.
What is RHYTHM PHARMACEUTICALS, INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, RHYTHM PHARMACEUTICALS, INC. has approximately 24.0 months of cash runway.
What is RHYTHM PHARMACEUTICALS, INC.'s market capitalization?
RHYTHM PHARMACEUTICALS, INC.'s market capitalization is approximately $6.6B.
Who is the CEO of RHYTHM PHARMACEUTICALS, INC.?
Dr. David P. Meeker M.D. is the chief executive officer of RHYTHM PHARMACEUTICALS, INC. (RYTM).
Get the full picture on RHYTHM PHARMACEUTICALS, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.